Wearable technologies are increasingly integrated into digital health systems to support continuous remote monitoring in oncology; however, the lack of standardized and reproducible criteria for device selection limits their scalable and regulation-compliant adoption in clinically oriented infrastructures. This study proposes a preclinical benchmarking framework for the systematic evaluation of commercially available wearable devices for oncology applications. Devices were assessed across six predefined dimensions: biometric data acquisition, application programming interface-based interoperability, regulatory compliance, battery autonomy, cost, and absence of mandatory subscription fees. From an initial pool of 23 devices, a stepwise screening process identified 6 eligible wearables, which were compared using a semi-quantitative weighted scoring system. The benchmarking analysis identified the Withings ScanWatch 2 as the highest-ranked device, achieving a score of 37/40 and representing the only solution combining medical-grade certification for selected functions, extended battery life (up to 30 days), declared General Data Protection Regulation-compliant data governance, and fully accessible application programming interfaces. The remaining devices scored between 17 and 23 due to limitations in certification, battery autonomy, or data accessibility. This work introduces a reproducible preclinical benchmarking methodology that supports transparent wearable device selection in oncology and provides a foundation for future scalable digital health integration under appropriate regulatory and interoperability governance.
A Benchmarking Framework for Cost-Effective Wearables in Oncology: Supporting Remote Monitoring and Scalable Digital Health Integration
Bindi, Bianca;Parretti, Chiara;Arcidiacono, Gabriele;
2026-01-01
Abstract
Wearable technologies are increasingly integrated into digital health systems to support continuous remote monitoring in oncology; however, the lack of standardized and reproducible criteria for device selection limits their scalable and regulation-compliant adoption in clinically oriented infrastructures. This study proposes a preclinical benchmarking framework for the systematic evaluation of commercially available wearable devices for oncology applications. Devices were assessed across six predefined dimensions: biometric data acquisition, application programming interface-based interoperability, regulatory compliance, battery autonomy, cost, and absence of mandatory subscription fees. From an initial pool of 23 devices, a stepwise screening process identified 6 eligible wearables, which were compared using a semi-quantitative weighted scoring system. The benchmarking analysis identified the Withings ScanWatch 2 as the highest-ranked device, achieving a score of 37/40 and representing the only solution combining medical-grade certification for selected functions, extended battery life (up to 30 days), declared General Data Protection Regulation-compliant data governance, and fully accessible application programming interfaces. The remaining devices scored between 17 and 23 due to limitations in certification, battery autonomy, or data accessibility. This work introduces a reproducible preclinical benchmarking methodology that supports transparent wearable device selection in oncology and provides a foundation for future scalable digital health integration under appropriate regulatory and interoperability governance.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
